Nutra Pharma Begins Drug Registration Process in India for Nyloxin -- A Treatment for Moderate to Severe Chronic Pain Nutra Pharma Has Begun the Drug Registration Process in India for Its Nyloxin Line of Pain Relievers; The Company Is Also Seeking a Relationship With an India-Based Pharmaceutical Company to Support the Launch, Marketing and Sales of Nyloxin Throughout India , a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), Multiple Sclerosis (MS) and Pain, announced today that it has begun the drug registration process in India for its Nyloxin line of pain relievers.
According to a 1998 study published in the Journal of the American Medical Association (JAMA), it was estimated that 19% of patients evaluated in India suffered from persistent pain. An additional 2007 report from the Journal of Pain and Symptom Management, documented that only 0.4% of India's population in need of opioids for pain relief had access to them.
